Reversal of antigen-dependent signaling by two mutations in antibody/receptor chimera: implication of inverse agonism in cytokine receptor superfamily

Biochemical Pharmacology
Masahiro KawaharaTeruyuki Nagamune

Abstract

Understanding the receptor activation mechanism is essential for the rational design of pharmacologically active ligand molecules. However, the activation mechanism of most cytokine receptors remains still unclear, and while agonism and antagonism have been described for ligand-mimetic peptides, there has been no report of inverse agonism that has been characterized for G protein-coupled receptors (GPCRs). To explore the activation mechanism of cytokine receptors, here we tried to investigate how agonism and antagonism could be altered by randomizing antibody variable region of an antibody/cytokine receptor chimera recognizing hen egg lysozyme (HEL) as an agonist. Based on our previous finding that the co-expression of V(H)-gp130 and V(L)-erythropoietin receptor (EpoR) chimeras transduced strict and efficient HEL-dependent cell growth signal, a V(H)-gp130 library encoding four randomized CDR2 residues was retrovirally infected to IL-3-dependent Ba/F3 cells already transfected with V(L)-EpoR. The selection without IL-3 resulted in a clonal expansion of the transduced cells, and interestingly some of which showed HEL dose-dependent growth suppression. Our results clearly indicate that agonism and antagonism of the antibody/cytoki...Continue Reading

References

Oct 4, 1996·The Journal of Biological Chemistry·S ElliottG Elliott
Dec 16, 1997·Proceedings of the National Academy of Sciences of the United States of America·S DamjanovichT A Waldmann
Jan 27, 1998·Journal of Biochemistry·T KimuraY Watanabe
Jun 23, 1999·Proceedings of the National Academy of Sciences of the United States of America·T NarandaL Olsson
Aug 17, 1999·Biochemical Pharmacology·A Christopoulos, E E El-Fakahany
Oct 16, 1999·Proceedings of the National Academy of Sciences of the United States of America·S A QureshiD F Mark
Dec 2, 1999·Experimental Cell Research·D M WojchowskiT J Pircher
Dec 8, 2000·Biochemical Pharmacology·P J Pauwels
May 16, 2002·The Journal of Biological Chemistry·Jens S GreiserHeike M Hermanns
Jul 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Jürgen GentGer J Strous
Apr 17, 2003·Molecular and Cellular Biology·Perry M ChanRobert Rottapel
May 30, 2003·The Biochemical Journal·Peter C HeinrichFred Schaper
Oct 20, 2005·Journal of Bioscience and Bioengineering·Masahiro KawaharaTeruyuki Nagamune

❮ Previous
Next ❯

Citations

Nov 13, 2008·Cytotechnology·Masahiro KawaharaTeruyuki Nagamune
Aug 9, 2013·Biotechnology Progress·Kenichiro OgawaTeruyuki Nagamune

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Cell Wall Structure (ASM)

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacterial Cell Wall Structure

Bacterial cell walls are made of peptidoglycan (also called murein), which is made from polysaccharide chains cross-linked by unusual peptides containing D-amino acids. Here is the latest research on bacterial cell wall structures.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.